

UC San Diego

UC San Diego Previously Published Works

Title

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.

Permalink

<https://escholarship.org/uc/item/60g5m9v0>

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10)

ISSN

1078-0432

Authors

Patel, Sandip P
Othus, Megan
Chae, Young Kwang
et al.

Publication Date

2020-05-01

DOI

10.1158/1078-0432.ccr-20-0790

Peer reviewed

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—
Response

Sandip P. Patel, Megan Othus, Young Kwang Chae, and Razelle Kurzrock

As Sonbol and Halfdanarson kindly point out, the lack of central pathology review with utilization of local pathology reports necessitated use of the 2010 WHO criteria for the neuroendocrine cohort in the S1609 DART study. We agree that central pathology review for these rare tumors would be best. In addition, MSI-status was not required, but will be tested on archival specimens as part of our translational objectives and is a focus of the dedicated high-grade neuroendocrine cohort currently underway within S1609.